Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T22:33:14.280Z.
Calculation as of: 2026-10-06T22:33:14.280Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2f5c47113f9c506e2e082fd2a1fe30760bd520268ada69101bb9e18573fa4dd9
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$870.81M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$857.16M
EV/EBITDA Ratio
N/A
TTM Avg
19.31x
3Y Avg
12.44x
5Y Avg
8.61x
Market Cap
$853.13M
EV/EBITDA Ratio
9.28x
TTM Avg
6.28x
3Y Avg
11.56x
5Y Avg
11.56x
Market Cap
$884.97M
EV/EBITDA Ratio
5.90x
TTM Avg
5.93x
3Y Avg
5.93x
5Y Avg
5.93x
Market Cap
$887.99M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| SI-BONE, Inc. (SIBN) | $867.03M | N/A | N/A | N/A | N/A |
| Odyssey Therapeutics, Inc. (ODTX)vs › | $870.81M | N/A | N/A | N/A | N/A |
| QuidelOrtho Corporation (QDEL)vs › | $857.16M | N/A | 19.31x | 12.44x | 8.61x |
| Alumis Inc. (ALMS)vs › | $855.38M | N/A | N/A | N/A | N/A |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $853.13M | 9.28x | 6.28x | 11.56x | 11.56x |
| SL Science Holding Ltd (SLBT)vs › | $852.35M | N/A | N/A | N/A | N/A |
| Arbutus Biopharma Corp (ABUS)vs › | $884.97M | 5.90x | 5.93x | 5.93x | 5.93x |
| Bioventus Inc. (BVS)vs › | $887.50M | 10.48x | 9.34x | 18.56x | 25.76x |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $887.99M | N/A | N/A | N/A | N/A |
| Pacific Biosciences of California, Inc. (PACB)vs › | $838.62M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
